The WP1 aims to establish lipidomic profiling of the health-to-CVD transition to distinguish between resolving and non-resolving inflammation.
During the first 18 months the focus has been on methodology development for full lipidomic profiling, and the application of the methods in selected samples from the CARE-IN-HEALTH cohorts.
The WP2 aims to explore lipid immunology with a focus on understanding how lipid mediators influence immune responses. The objectives include providing functional, molecular, immune-metabolic, and immuno-thrombosis data to the CARE-IN-HEALTH atlas, aiding in the identification and validation of targets for diagnosing, preventing, and treating the health-to-CVD transition.
During the first 18 months, we focused on developing and standardizing methodologies for studying lipid-mediated immune responses. Significant accomplishments include standardizing cell culture conditions, identifying key immunometabolic pathways regulating immune and vascular responses, and creating bioinformatic platforms for EV dataset analysis.
The WP3 aims to establish the associations of chronic non-resolving inflammation with the full continuum of the health-to-CVD transition, in three cohorts monitoring i) prevalent, ii) subclinical, iii) incident CVD.
During the first 18 months collection of available data on clinical characteristics, genetic variations, lipid exposure by dietary intake, and biomarkers from 3 large cohorts has allowed initiation of epidemiological analyses for the health-to-CVD transition outcome measures.
The WP4 aims to retro- and prospectively determine the impact of dietary lipid interventions on systemic and local lipid-driven/regulated inflammation on the health-to-CVD transition and to provide proof-of-concept for the care-in-health applications
During the first 18 months the retrospective analysis of GISSI Prevenzione and GISSI-HF (n=20000) has started and it will allow to explore the effects of n-3 polyunsaturated Fatty Acids (PUFA) 1 g/day on circulatory measures of immunology and lipidome. Two smaller proof-of-concept studies, POMEGA-2 and RESOLVIN will extend and complement information derived from the GISSI studies.
The WP5 aims the integration, curation, harmonization and standardization of existent and produced data resources to be used for machine learning approaches to identify personalized factors predicting resolving vs. non-resolving inflammation, the critical lipid mediators, and how to predict different stages of the health-to-CVD transition outcome measures.
During the first 18 months we began integrating and harmonizing data into the CARE-IN-HEALTH Atlas, laying the groundwork for the development of the CARE-IN-HEALTH MCDSS.
The WP6 aims to develop and validate a point-of-care cardiovascular disease (CADIS) diagnostic tool (biosensor) prototype for non-technical users/ healthcare professionals to identify and prevent the health-to-CVD transition.
During the first 18 months I3S has developed the AptaShield sensor technology for high-throughput biomarker quantification, applicable to both optical and electrochemical detection. Additionally, I3S has implemented an advanced quality control system for the fabrication and functionalization of electrochemical sensing devices.
The WP7, 8 and 9 aim to ensure the effective communication and dissemination of project results, maximize the exploitation of research outcomes, provide robust project management and governance, and uphold the highest ethical standards.
During the first 18 months these WPs have facilitated streamlined administrative processes and smooth communication both within and outside the consortium. Additionally, it has been initiated the development of a strategic plan has been initiated to broaden impact of the project findings.
